522 results about "Medium chain fatty acid" patented technology

The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

Provided herein are blends oils or fatty acids comprising more than 50% medium chain fatty acids, or the fatty acid alkyl esters thereof, and having low melting points. Such blends are useful as a fuel or as a starting material for the production of, for example, a biodiesel. Also provided genetically altered or modified plants, modified such that the amount of medium chain fatty acids generated by the plant are increased. Further provided is a method of predicting the melting point of a blend of fatty acid methyl esters and the use of such a method for identifying blends suitable for use as, for example, a biodiesel.

The invention relates to a pharmaceutical composition and oral dosage forms comprising an HDAC inhibitor in combination with an enhancer to promote absorption of the HDAC inhibitor at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

The invention relates to a pharmaceutical composition, particularly oral dosage forms, comprising a DAC inhibitor in combination with an enhancer to promote absorption of the DAC inhibitor at the GIT cell lining. The enhancer is a medium chain fatty acid or derivative thereof having a carbon chain length of from 6 to 20 carbon atoms. In certain embodiments, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to promote absorption of the bisphosphonate at the GIT cell lining. The enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.

The invention relates to a solid oral dosage form comprising a pharmaceutically active ingredient in combination with an enhancer which enhances the bioavailability and/or the absorption of the active ingredient. Accordingly, a solid oral dosage form comprises a drug and an enhancer wherein the enhancer is a medium chain fatty acid ester, ether or salt or a derivative of a medium chain fatty acid, which is, preferably, solid at room temperature and which has a carbon chain length of from 6 to 20 carbon atoms. Preferably, the solid oral dosage form is controlled release dosage form such as a delayed release dosage form.

Beta-hydroxybutyrate mineral salts in combination with medium chain fatty acids or an ester thereof such as medium chain triglycerides were used to induce ketosis, achieving blood ketone levels of (2-7 mmol/L), with or without dietary restriction. The combination results in substantial improvements in metabolic biomarkers related to insulin resistance, diabetes, weight loss, and physical performance in a short period of time. Further, use of these supplements to achieve ketosis yields a significant elevation of blood ketones and reduction of blood glucose levels. Use of these substances does not adversely affect lipid profiles. By initiating rapid ketosis and accelerating the rate of ketoadaptation, this invention is useful for the avoidance of glucose withdrawal symptoms commonly experienced by individuals initiating a ketogenic diet, and minimizes the loss of lean body mass during dietary restriction.

The present invention provides methods and compositions for production of algal-based medium chain fatty acids and hydrocarbons. More specifically, the invention relates to a Nannochloropsis algal strain and mutants that produces high amounts of C16 fatty acids and hydrocarbons. The present invention provides methods and compositions for production of algal-based medium chain fatty acids and hydrocarbons. More specifically, the invention relates to a Nannochloropsis algal strain and mutants that produces high amounts of C16 fatty acids and hydrocarbons.

Ketogenic compositions including a beta-hydroxybutyrate (BHB) mixed salt are formulated to induce or sustain ketosis in a subject to which the ketogenic compositions are administered. The BHB mixed salt is formulated to provide a biologically balanced set of cationic electrolytes, and is formulated to avoid detrimental health effects associated with imbalanced electrolyte ratios. A ketogenic composition includes BHB salts of at least sodium, potassium, calcium, and magnesium. The BHB salts may also include at least other component such as a BHB compound containing other cations, such as transition metal cations (e.g., zinc or iron), a BHB-amino acid salts, medium chain fatty acid source, vitamin D₃, flavorant, or other excipient.

The invention provides a comprehensive nutritional and semi-digested formulated food for special medical use, and a preparation method thereof. Every 100 g of the comprehensive nutritional and semi-digested formulated food for special medical use comprises 5-15 g of hydrolyzed whey protein, 3-8 g of egg white protein, 1-4 g of soy isolate protein, 1-4 g of concentrated whey protein, 0.5-2 g of sodium caseinate, 37-60 g of carbohydrate with a low GI value, 1-4 g of fructose oligosaccharide, 0.005-0.05 g of carboxymethyl pachymaran, 15-22 g of vegetable oil powder, 4-10 g of a medium-chain fatty acid, 3-8 g of a mineral premix and 0.2-1.4 g of a vitamin premix. A finished product is prepared by mixing the above components uniformly. With a synergistic effect of the above components, partial digestion functions of a patient after operation can be taken fully used to keep, maintain and promote comprehensive restoration of the digestion functions of the patient; an immune function can be regulated; and body disease-resistant ability can be enhanced, thereby influencing development and conversion of the disease.

The invention provides a novel self-emulsifying drug delivery system (SEDDS). An SEDDS carrier material comprises a surfactant and an oil phase containing Capmul MCMs and medium chain fatty acids, is suitable for loading pH-dependent (weakly acidic and weakly alkaline) and a pH-independent (neutral) insoluble medicines, greatly improves the solubility of the medicines to realize optimum bioavailability, and has important application values in the development of preparations of the insoluble medicines.

Compositions and methods for improving cardiovascular health in the elderly by delivering a selection of essential amino acids, phytosterols, stanols, and isoflavones, which may be supplemented with a low glycemic carbohydrate and/or a medium chain fatty acid.

The invention discloses a production method for medium-chain and long-chain oil fatty acid. The production method comprises the following steps: carrying out transesterification reaction, saturated alkaline water neutralization, adsorbent desoaping, vacuum flashing and the like to medium-chain fatty acid triglycerides of C6-C12 and long-chain fatty acid triglycerides of C16-C24 in a reactor filled with lipase, to obtain the long-chain oil fatty acid in the product. The method solves the difficulty that the medium-chain and long-chain oil fatty acid in the prior art is complicated, and has the characteristics of being short in reaction time of the reactor, and low in energy consumption.

This invention is directed generally to compositions (including foods, supplements, treats, toys, etc.) for animal consumption, particularly compositions that tend to aid in weight loss or reduction in weight gain, and particularly compositions that comprise one or more medium chain fatty acid triglycerides (“MCT”). This invention also is directed generally to methods for using such compositions. This invention is further directed generally to processes for making such compositions.

The invention discloses a polyphyly fat mixture for feeding animals, which is formed by mixing more than two greases. The mixture comprises long chain fatty acid and medium chain fatty acid, and the weight ratio of the long chain fatty acid to the medium chain fatty acid is 30-90:60-10. A microcapsule applying the polyphyly fat mixture for feeding animals comprises the following raw materials in percentage by weight: 25-80 percent of olyphyly fat mixture, 0.8-4 percent of complex emulsifying agent F, 0.8-4 percent of sodium stearoyl-2-lactylate, 0.3-5 percent of sodium caseinate and 10-70 percent of encrusting substance. The polyphyly fat mixture accords with the growth performance of animals and ensures that the production performance of the animals can be fully expressed. Experiments prove that after feeding the polyphyly fat mixture, the fresh of piggies is improved by 3.96 compared with piggies fed with single derived fat feed. By adopting the fatty acid mode and fat products, after feeding nursing sows, the weight of weaning litter of the piggies is improved by 3.96 percent. After feeding the polyphyly fat mixture, the fresh of broiler chickens is improved by 3.96 percent compared with broiler chickens fed by single derived fat.

The present invention generally relates to orally administered pharmaceutical compositions of iron compounds with medium chain fatty acid salts. The invention further relates to methods of using the pharmaceutical compositions to treat iron deficiency and related disorders.

The invention provides a structural type triglyceride rich in medium-chain fatty acid and a preparation method thereof. The provided triglyceride is prepared from medium-chain fatty acid with a carbon number of 8-12, palmitic acid, glycerin, and long-chain unsaturated fatty acid/fatty acid ester through catalytic reactions. In the provided triglyceride, medium-chain fatty acid accounts for 11 to 40 wt% of total fatty acid; Sn-2 position saturated fatty acid accounts for 52 to 80 wt% of total saturated fatty acid; Sn-1,3 position unsaturated fatty acid accounts for 80 to 95 wt% of total unsaturated fatty acid, the content of Sn-USU type triglyceride is 40 to 80%, and the content of triglyceride palmitate is 3 to 8%. The provided triglyceride has the characteristics of medium-chain triglyceride and long-chain triglyceride; compared with the common medium/long-chain fatty acid edible oil, the provided triglyceride has richer structures, according to the product characteristics, and the provided triglyceride can be used as a food nutrient supplement and added in different food formulas. The preparation method has the characteristics of high production efficiency, low energy consumption, mild reaction conditions, little using amount of enzyme, more precise procedure, and effectively-reduced cost.

The invention relates to the technical field of treatment and resourceful utilization of organic waste and aims at providing a resourceful treatment method for organic waste. The resourceful treatment method can improve the economic benefits of fermentation products. According to the adopted technical scheme, the method includes the steps of lactic acid fermentation, carbon chain lengthening and medium-chain fatty acid extracting, wherein according to carbon chain lengthening, microorganisms for synthesizing medium-chain fatty acid are added for anaerobic fermentation; and the organic waste is biodegradable organic waste. The brand new organic waste treatment method is provided, in other words, the technology for synthesizing medium-chain fatty acid as the main product through coupling of organic matter hydrolysis lactic acid generating and carbon chain lengthening is provided. The principle of the technology is obviously different from a previous anaerobic biochemical treatment technology, harmlessness and stability of organic waste are achieved, meanwhile, medium-chain fatty acid which is easy to extract and has high economic benefits can be generated, organic matter such as ethyl alcohol does not need to be additionally added, the technological cost is greatly reduced, and the economic benefits of the technology are obviously reduced.

The invention relates to child care pig compound feed without a tensile body, and the child care pig compound feed is prepared from the following components: corn, peeled soybean meal, puffed soybean meal, fermented soybean meal, steam white fish meal, flour, soybean oil, mountain flour, calcium hydrogen phosphate, edible salt, child car pig compound premix, coated slow-release acidifier, L-lysine hydrochloride, DL methionine, L-thronine, tryptophan, octanoic/decanoic acid glyceride, yeast nucleic acid, xylo-oligosaccharides, sodium glutamate, sodium butyrate, the root of Chinese pulsatilla, coptis chinensis, golden cypress, ash bark, choline chloride and phytase. The child care pig compound feed without the tensile body provided by the invention starts from the physiological characteristics of a child care pig, adopts multiple combinations of raw materials, is complementary in nutrition, designs amino-acid-balanced, calcium-phosphate-balanced and electrolyte-balanced daily ration, adds no antibiotic, adopts medium-chain fatty acid and natural Chinese herbal medicine additive for health protection, and can be used for improving food consumption of the child care pig, reducing the feed conversion ratio, improving intestinal health of the child care pig, improving immunity and drawing a skeleton of the child care pig, so that a good foundation is laid for later-stage growth.

Use of a composition comprising a compound of any of formulae I, II, Ila, III and Illa; or a combination thereof wherein each R₁ is independently C_7-11 alkyl; A and B are independently H or CO—R₁; R₂ is H or C_1-4 alkyl; M is a metal monocation (k=1) or dication (k=2); Y is 0 or NH; and Z is 0, NH, CH₂O or a bond; for the manufacture of a medicament for stimulating erythropoiesis. Preferably, the composition further comprises human erythroporietin.

The present invention provides pharmaceutical compositions which are effective in providing therapeutically effective blood levels of a therapeutically active ingredient to a subject when administered to a gastrointestinal tract. In one aspect, the pharmaceutical compositions comprise a therapeutically effective amount of a therapeutically active ingredient; at least one water soluble enhancer, e.g., a medium chain fatty acid or a salt, ester, ether, or derivative of a medium chain fatty acid and has a carbon chain length of from about 4 to about 20 carbon atoms; and a saccharide.